ARTICLE | Finance
FDA behind; IPO in front
Trius: Regulatory pathway for antibacterial drug now clear; ready to IPO
July 19, 2010 7:00 AM UTC
Trius Therapeutics Inc. believes it has addressed the FDA issues that caused it to delay its IPO in March and hopes to price the deal next week.
The company plans to sell 6 million at $12-$14 through underwriters are Citigroup; Piper Jaffray; Canaccord; and JMP Securities. At the mid-point, Trius would raise $78 million...